A grand celebration of insurance knowledge and honor, united in wisdom and glory. KUALA LUMPUR, Malaysia, Aug. 10, 2024 /PRNewswire/ — The 15th Worldwide Chinese Life Insurance Congress & 2024 IDA Annual Conference is being held at the Malaysia International Trade and Exhibition Centre (MITEC) from August 9 to 12, 2024. This year’s theme, “CHANGE […]
Category Archives: Pr Newswire
Pr Newswire
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
10
Aug
Aug
TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules) is disappointed in the decision made by the US Food and Drug Administration (USFDA) to request […]
Pr Newswire
ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
10
Aug
Aug
KEY HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease on track to begin H2-2024. Obesity with related metabolic complications selected as lead indication for Inflammasome ASC Inhibitor IC 100. Supportive data from preclinical study in atherosclerosis, a common obesity-related metabolic complication, is expected to be available H2-2024. […]
10
Aug
Aug
Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1 inhibitor in Q3 2024 SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today […]
10
Aug
Aug
CAMBRIDGE, Mass., Aug. 09, 2024 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to four new employees. Fulcrum granted stock options to purchase shares of the […]
10
Aug
Aug
Tinlarebant, a novel oral therapy, is intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) Phase 1b & 2/3 (“DRAGON II”) trial of Tinlarebant in adolescent STGD1 patients has been initiated and have completed enrollment for Phase 1b with six […]
HOUSTON, Aug. 10, 2024 /PRNewswire/ — On August 8, 2024, SEG Solar (SEG), a leading U.S. photovoltaic manufacturer, held a grand opening ceremony for its new PV manufacturing base in Houston, Texas, marking a new chapter in SEG’s commitment to U.S. domestic manufacturing. During the ceremony, the first 585W YUKON N series module rolled off the […]
Strong Revenue Growth and Strategic Advances Across Key Segments, Enhances Commitment to ESG and Sustainable Development Impressive Financial Growth: The group reported a 43.5% increase in revenue, driven by a 156% boost in cell therapy revenue and a 75.4% rise in gross profit, showcasing strong performance across key segments. Focused on Innovation and Efficiency: Investing […]
NEW YORK, Aug. 9, 2024 /PRNewswire/ — Global IBO Group Ltd. (“GIBO”), a unique and integrated AIGC animation creation and streaming platform for storytellers and content creators, and Bukit Jalil Global Acquisition 1 Ltd. (“Bukit Jalil Global”) (Nasdaq: BUJA), a publicly traded special purpose acquisition company, today announced that they have entered into a definitive […]
LONDON and NEW YORK, Aug. 9, 2024 /PRNewswire/ — Today, i2 Group said increasing demand for its intelligence analytics software among NATO forces and intelligence and law enforcement agencies was driving the company’s double-digit growth. The global leader in visual data analysis today reported an annual 18% uptick in software license sales and 10% workforce growth as […]